Lonza Walkersville, Inc.

Lonza Walkersville, Inc., a foreign-owned manufacturer of biological materials, cell culture media, transfection devices, and specialized laboratory equipment, operates as a prime contractor supplying biomedical research products and scientific instrumentation to federal agencies through direct purchase orders and blanket purchase agreements with no set-aside designations. The company competes in full-and-open procurements across the federal research enterprise and holds primary NAICS classifications in pharmaceutical preparation manufacturing (190 awards), in-vitro diagnostic substance manufacturing (143 awards), and analytical laboratory instrument manufacturing (85 awards).

Lonza Walkersville's federal customer base concentrates heavily in civilian life-sciences agencies. The National Institutes of Health dominates the footprint—the NIH Office of the Director leads by award count with 169 awards ($849 thousand combined potential value), while the NIH National Heart Lung and Blood Institute anchors the dollar ranking with 25 awards carrying $17.6 million combined potential value. The NIH Office of Logistics and Acquisition Operations (26 awards, $10.2 million) reflects Lonza Walkersville's role as a BPA holder. The Food and Drug Administration places 36 awards ($1.1 million), the NIH Clinical Center 40 awards ($1 million), and the Department of the Army Medical Command 34 awards ($412 thousand). Together, these top five customers by award count represent 30% of awards; the top five by potential value cover 85% of combined potential value—a substantial concentration in NIH institutes and supporting agencies. Lonza Walkersville also serves the Department of Veterans Affairs and the National Institutes of Health's constituent institutes including the National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Heart Lung and Blood Institute, and National Institute on Drug Abuse, among others across 67 distinct customer agencies overall.

The vendor's primary vehicle position is a $10 million single-award Blanket Purchase Agreement with the HHS Office of Logistics and Acquisition Operations, valid through December 31, 2026, enabling streamlined procurement of biological materials, blood products, cell culture media, laboratory supplies, and medical and scientific equipment and repair services. This BPA has generated significant task-order activity with 180 task orders under HHSN263199900049886B ($1 million combined potential value), 46 task orders under HHSN263201600052B ($544 thousand), and ongoing calls for research reagents, Nucleofector systems, specialized cell lines, and balanced salt solutions. Recent named contract examples include a $225.4 thousand purchase order from the FDA (September 2023) for immunogenicity assessment of peptide-activated CD4+ T cells, a $86.4 thousand purchase order from the FDA (August 2025) for human cells and cell culture reagents, a $52.2 thousand purchase order from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (September 2024) for a Nucleofector system to study autoantibody internalization, and a $40.7 thousand purchase order from the FDA (July 2024) for Biopredic International NoSpin HepaRG cells supporting cytotoxicity and genotoxicity testing of small-molecule nitrosamines.

Activity has declined modestly—15 awards in 2022, 18 in 2023, 14 in 2024, dropping to 5 in 2025 and 3 through March 2026—but the combined potential value across the full portfolio remains substantial at $36.4 million, with $11.9 million obligated (33%). Only 3 awards totaling $129 thousand face ultimate completion within the next twenty-four months, indicating minimal recompete exposure in that window. The vendor holds no material sub-award footprint; sub-awards account for 0% of activity, with only two recent sub-placements listed: a March 2026 sub-award with Weems Design Studio, Inc. for centralized chemopreventive agent repository and chemistry support, and a January 2026 sub-award with Research Triangle Institute for chemistry services to the National Toxicology Program.

Lonza Walkersville is part of the global Lonza Group Ltd. corporate structure. Named U.S. subsidiaries include Lonza LLC, Arch Chemicals Inc., Capsugel Inc., Lonza Sales AG, and Lonza Rockland Inc., each operating as a for-profit manufacturer of goods. The Walkersville Division specifically performs work from its Walkersville, Maryland facility and occasionally from subordinate locations including Silver Spring, Maryland and San Diego, California. The company's federal award footprint spans nearly thirty-five years of activity, with origins in 1991, demonstrating sustained relationships as a critical supplier of cell culture media, transfection instrumentation (4D Nucleofector systems), specialized cell types (primary cells, endothelial cells, hepatocytes), and laboratory reagents essential to NIH intramural research operations across cancer, cardiovascular, neurological, immunological, and translational science programs.